Prof Dolcetti is a clinician scientist with MD specializations in Oncology and Clinical Immunology with >20 y research experience in cancer biology and immunology. As Director of the Cancer Bio-Immunotherapy Division at the CRO-National Cancer Institute of Aviano, Italy, he performed cutting-edge science on the pathogenesis of infection-driven tumours and developed novel immune-based therapies for lymphomas, breast cancer and melanoma. He designed and co-led clinical trials of immunotherapy for cancer patients, particularly those with breast cancer. In 2015, he relocated to Brisbane as Chair in Cancer Medicine, Diamantina Institute, Univ. of Queensland, where he coordinated the Cancer Immunotherapy Program, developed new cancer vaccines and improved combination immunotherapies. In 2020, he took the role of Head, Clinical and Translational Immunotherapy as joint appointment at the Sir Peter MacCallum Cancer Centre, Univ. of Melbourne and Victorian Comprehensive Cancer Centre. His major research contributions are: demonstration in pre-immunotherapy era that the good prognosis of MSI-H colon cancer patients was significantly associated with high numbers of activated CD8+ TILs, providing the rationale for subsequent adoption of immune checkpoint inhibitors; development of “off-the-shelf” idiotypic vaccines for lymphomas; development of a therapeutic antibody and an innovative adoptive immunotherapy for EBV-driven tumours; identification of immunological correlates of pathological complete response in breast cancer patients treated with neoadjuvant immuno-chemotherapy; development of a nanoemulsion-based vaccination platform delivering antigens to cross-presenting dendritic cells in vivo. He has >250 publications in peer-reviewed international journals with >10,000 citations. He had the privilege to be the President of the Italian Society for Cancer Research in 2012-13.